ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MLNT Melinta Therapeutics Inc

0.50
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Melinta Therapeutics Inc NASDAQ:MLNT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.50 0.51 0.5198 0 01:00:00

Initial Statement of Beneficial Ownership (3)

25/10/2019 5:54pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lococo Ryan

2. Date of Event Requiring Statement (MM/DD/YYYY)
10/17/2019 

3. Issuer Name and Ticker or Trading Symbol

MELINTA THERAPEUTICS, INC. /NEW/ [MLNT]

(Last)        (First)        (Middle)

C/O MELINTA THERAPEUTICS, INC., 44 WHIPPANY ROAD

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Operating Officer /

(Street)

MORRISTOWN, NJ 07960      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Melinta Common Stock  (1)6/13/2028 Melinta Stock Option (right to buy) 5620.0 $41.25 D  
Melinta Common Stock  (2) (2)Melinta Restricted Stock Units 100000.0  (2)D  

Explanation of Responses:
(1) Shares will vest 25% on the first anniversary of the award, June 14, 2019, then ratably over the following 36 months.
(2) The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to continued service with the Issuer through the applicable vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Lococo Ryan
C/O MELINTA THERAPEUTICS, INC.
44 WHIPPANY ROAD
MORRISTOWN, NJ 07960


Chief Operating Officer

Signatures
/s/ Russell E Causey, by Power of Attorney10/25/2019
**Signature of Reporting PersonDate

1 Year Melinta Therapeutics Chart

1 Year Melinta Therapeutics Chart

1 Month Melinta Therapeutics Chart

1 Month Melinta Therapeutics Chart

Your Recent History

Delayed Upgrade Clock